Nippon Shinyaku Co., Ltd. (TYO:4516)
4,904.00
+69.00 (1.43%)
At close: Mar 5, 2026
Nippon Shinyaku Revenue
Nippon Shinyaku had revenue of 47.49B JPY in the quarter ending December 31, 2025, with 13.10% growth. This brings the company's revenue in the last twelve months to 166.05B, up 5.87% year-over-year. In the fiscal year ending March 31, 2025, Nippon Shinyaku had annual revenue of 160.23B with 8.08% growth.
Revenue (ttm)
166.05B
Revenue Growth
+5.87%
P/S Ratio
1.96
Revenue / Employee
74.03M
Employees
2,243
Market Cap
325.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 160.23B | 11.98B | 8.08% |
| Mar 31, 2024 | 148.26B | 4.08B | 2.83% |
| Mar 31, 2023 | 144.18B | 6.69B | 4.87% |
| Mar 31, 2022 | 137.48B | 15.60B | 12.80% |
| Mar 31, 2021 | 121.89B | 5.25B | 4.50% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Toho Holdings | 1.54T |
| Sumitomo Pharma | 453.40B |
| Towa Pharmaceutical | 269.92B |
| Sawai Group Holdings | 200.68B |
| Tsumura & Co. | 189.50B |
| Hisamitsu Pharmaceutical Co. | 159.27B |
| KYORIN Pharmaceutical | 133.26B |
| Mochida Pharmaceutical | 111.92B |